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that condition) and increases the mortality probability as time progresses (reﬂecting 
patients that entered the trial with less severe and undetected cases of the condition 
or who developed the condition during the trial). Mortality was phased-in for four 
conditions reﬂective of their high prevalence and consistency with exclusion criteria: 
CHD, malignant neoplasms, chronic lower respiratory disease, and liver disease. 
RESULTS: To statistically compare the ACAS simulated versus actual mortality sur-
vival curves, we calculated the absolute differences between the curves and performed 
a standard equality of probabilities test on the curves at 12, 24, 36, 48, and 60 months. 
For the ACAS curve without mortality phase-in, at all times t before 60 months the 
simulated and actual curves had a statistically signiﬁcant difference (0 < p < 0.04). 
With mortality phase-in, there was no evidence at any time t that the simulated and 
actual curves had a statistically signiﬁcant difference (0.62 < p < 0.95). CONCLU-
SIONS: Phasing in mortality probabilities for trial-excluded conditions can simulate 
mortality survival curves that reﬂect the control arms of clinical trials.
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OBJECTIVES: It is well documented that standard logit regressions are biased in rare 
events. We wanted to illustrate how to analyze rare events in observational analysis 
using Medicare claims data. In particular, we compared the operational mortality for 
patients who underwent hip fracture surgery and suffered venous thromboembolism 
(VTE). METHODS: We applied two correction methods to address possible rare event 
bias. The ﬁrst method involved obtaining information about the fraction of those in 
the population and the observed fraction of those in the sample. We estimated the 
adjusted constant coefﬁcient in the logit model. In the second method, we weighted 
the proportion of ones and zeros in the sample to equal the true proportion in the 
population. We tested for differences in predicted probabilities using a non-parametric 
test. The Mann-Whitney U test and Kolmogorov-Smirnov two sample test can both 
be used on predicted probabilities of logit regression to see whether differences exist. 
RESULTS: To apply the methodology, we constructed a retrospective cohort study 
comparing the operational death rate between patients who underwent hip replace-
ment surgery who suffered VTE and patients who did not suffer VTE. 60,245 patients 
with hip fracture surgery were identiﬁed from the 100% Medicare Inpatient dataset. 
Mortality was rare (0.81% vs. 3.34% for patients with non-VTE vs. VTE). Using 
Monte Carlo simulation, the unadjusted rate was 0.97% for non-VTE patients and 
4.36% for VTE patients. The odds ratio was 3.98 for the standard model, 3.98 for 
the prior correction method, and 4.37 for the weighted mechanism. The predicted 
event probabilities were signiﬁcantly different. CONCLUSIONS: Standard logit 
regression is proven to underestimate probabilities with rare events. We examined two 
correction methods. The predicted event probabilities adjusted for rare event bias were 
signiﬁcantly different from the unadjusted ones.
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OBJECTIVES: The Comparative Effectiveness Index (CEI) provides a quantitative 
method of transforming efﬁcacy data into effectiveness indices. In lieu of head-to-head 
randomized controlled trials, the CEI uses efﬁcacy, adherence, and safety data to 
facilitate the drug evaluation process by providing a single value index for each thera-
peutic alternative. METHODS: Efﬁcacy data from clinical trials serve as surrogate 
markers of effectiveness. In analyzing two hypothetical anti-hypertensive drugs, A and 
B, the efﬁcacy of each drug is ranked on a nominal scale based on the literature: A = 
10 and B = 8. The drug with the highest nominal value is the most efﬁcacious. 
However, this value needs to be moderated by adherence and safety data. Adherence 
rates, calculated from claims databases for example, are: A = 60% and B = 90%. The 
formula for calculating the Modiﬁed Efﬁcacy Score (MES) of each drug is the (adher-
ence rate*efﬁcacy score)/100: A = 6 and B = 7.2. Adverse events (AE) reported in the 
clinical trials are ranked based on severity, the scale is anchored at 0 and 100 where 
0 = No AE and 100 = Death. Each AE is assigned a value depending on its severity 
then multiplied by the probability of its incidence. This is repeated for each AE and 
summed. The inverse of the sum, the Adverse Events Score (AES), is used in the ﬁnal 
computation so that both MES and AES modiﬁers have a direct relationship with the 
CEI. The AES for the drugs are: A = 3.33 and B = 5.00. The MES is multiplied by the 
AES to calculate the CEI. Consequently, the CEI would be: A = 19.98 and B = 36.00. 
Although drug A was more efﬁcacious, drug B is more effective. CONCLUSIONS: 
The CEI provides health care decision-makers with valuable comparisons between 
therapeutic alternatives, but it requires further development and validation. Incorpo-
rating measures of dispersion for efﬁcacy and compliance in a sensitivity analysis can 
generate more comprehensive indices.
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THE NATIONAL BURDEN OF PEDIATRIC ADVERSE DRUG EVENTS: A 
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OBJECTIVES: Pediatric adverse drug events (ADEs) lead to substantial burden on 
patients, caregivers, and payers. The objective of the current study was to quantify 
the extent of the national pediatric ADE burden by determining (1 the frequency of 
ADE occurrence; (2 excess length of stay (LOS) and excess cost associated with 
hospitalization; and (3 the hospital, patient, and ADE characteristics that predict 
excess LOS and excess cost. METHODS: Using the 2006 Kids’ Inpatient Database, 
ADEs were identiﬁed using ICD-9 and supplemental Ecodes; ADE frequencies were 
computed. A hospitalization with an ADE was matched with 1 hospital visit without 
an ADE; matching criteria included the All Patient Reﬁned-Diagnosis Related Group, 
which accounts for severity of illness and risk of mortality, and gender and age. Excess 
LOS and excess cost (totals and means) were calculated for case-control pairs. An 
ordinary-least-squares regression was run, with the case-control pairs as observations, 
to determine signiﬁcant predictors of excess LOS and excess cost. RESULTS: In 2006, 
118,779 ADEs occurred in 99,320 visits out of 7,558,812 total pediatric hospitaliza-
tions. The mean excess LOS was 0.98 days (p < 0.0001), while the mean excess cost 
was $2,252 (p < 0.0001). Adverse effects from benzodiazepine-based tranquilizers, 
certain anticonvulsants, adrenal corticosteroids, and various antibiotics led to the 
highest excesses (all with p < 0.0001). The mean excess LOS and excess cost, respec-
tively, for neonates aged 0–7 days were 6.4 days (p < 0.0001) and $26,417 (p < 
0.0001). Statistically signiﬁcant predictors included age, hospital region, insurance 
coverage, hospital size, urban versus rural hospital location, major diagnostic category 
for hospital admission, and severity of illness. CONCLUSIONS: A substantial share 
of the pediatric ADE burden is accounted by adverse effects rather than accidental 
poisoning. Variation across regions, drug classes, and diagnoses suggests that efforts 
to reduce the ADE burden can be targeted to have the greatest impact.
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OBJECTIVES: The aim of the study is to determine the prevalence and use of poten-
tially inappropriate medication in elderly population according to the Beer’s criteria. 
METHODS: Data for the present study was obtained from National Nursing Home 
Survey (NNHS) 2004. Patients of the age 65 and above were taken as sample. The 
use of potentially inappropriate medication was assessed by ranking the rate of usage 
of the 48 medications listed in the Beer’s criteria that should be avoided in elderly 
patients and assessing the medication usage across demographics like gender and age. 
Descriptive statistics were carried out using SPSS 17. RESULTS: The total number of 
cases of the age 65 and above using the potentially inappropriate medication was 
2209. The top ﬁve most used drugs were ferrous sulfate ( 54.33%), Clonidine ( 7.8%), 
Lorazepam ( 6.9%), Biscodyl ( 6.9%) and Amioderone (5.7%). Other more used drugs 
were Nifedipine ( 2.6%), Amitryptyline ( 2.5%), Alprazolam (2.2%), Fluoxetine ( 
1.6%), Naprozen ( 1.4%), Temezepam (1.1%), Diazepam ( 0.95%) and Nitrofuroin-
toin (0.90%). The usage was more in female (73.7%) as compared to male (26.3%), 
it was more in the age group 85 to 100 ( 43.1%) compared to 65 to 74 ( 17.9%) and 
75 to 84 ( 39.1%). There were 2208 (91.8%) elders using at least one of the 48 medi-
cations and 181( 8.1%) elders using two of these 48 medications. CONCLUSIONS: 
The use of potentially inappropriate medication listed under Beer’s criteria is highly 
prevalent among the elderly. There is more usage in females compared to males and 
more in the age group 85 to 100. Among the top 12 drugs used, accept for Ferrous 
sulfate and Clonidine which has the low Beer’s severity rating, all other drugs have a 
high Beer’s severity rating and causes Adverse Drug Events.
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OBJECTIVES: To estimate the risks of gaining weight, with the use of selective 
serotonin reuptake inhibitors (SSRI) and atypical antipsychotics (SGA) in combination 
among children and adolescents. METHODS: A retrospective cohort study was con-
ducted using 2003–2005 Medicaid Analytic eXtract (MAX) data from four U.S. states. 
Combination pharmacotherapy was operationalized as the concurrent prescribing of 
SSRI and SGA, where at least 14 days of treatment overlap occurred. Long term 
combination use is deﬁned as an overlap beyond 60 days. Children and adolescents 
aged 6–18 years, and enrolled in Medicaid during 3 months prior and 1 year post the 
treatment initiation were selected. Multivariable logistic regression models were 
employed to estimate the risks of gaining weight during the one year follow up period. 
RESULTS: Among 118,126 children and adolescents received SSRI or SGA, 
56,091(12.5%) were on combination treatment and of which approximately 80% 
were on long-term therapy (>60 days). Vast majority (63%) of these recipients were 
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adolescents (13–18 years). The effect of combination therapy on risk of weight gain 
was observed against both SSRI monotherapy and SGA monotherapy in multivariable 
logistic regression analyses. Likelihood of gaining weight with combination therapy 
was higher against both SSRI monotherapy (OR = 1.88; 1.69–2.10) and SGA mono-
therapy (OR = 1.52; 1.37–1.68). Long-term combination therapy (>60 days of treat-
ment overlap) resulted into increased risk of weight gain (OR = 1.64; 1.30–2.07) as 
compared to short term uses (> = 14 days and <60 day). CONCLUSIONS: The effect 
of combination therapy on increased risk of weight gain was suggested in the study, 
especially when the combinations were used for long term maintenance. Comprehen-
sive evaluation of other psychotropic combinations on risk of other adverse events is 
needed to be conducted in future.
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STAY OF WOMEN WITH PRE-EXISTING MEDICAL CONDITIONS
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OBJECTIVES: Monitoring maternal morbidity is essential as per Healthy People 2010 
objectives. Maternal morbidity due to pre-existing medical conditions (PEC’s) is found 
to be an important determinant of delivery complications. With limited literature for 
the inﬂuence of PEC’s on obstetric hospitalization, the objective of this study was to 
assess the effects of PEC’s on length of stay (LOS) during child delivery. METHODS: 
The 2006 National Hospital Discharge Survey (NHDS) was used as the data source. 
PEC’s included diagnosis of chronic hypertension, diabetes mellitus, anemia, asthma, 
thyroid disorder or cardiac disease before conception. Cox Proportional Hazards 
Model was performed to ascertain the relationship between PEC’s and LOS in the 
presence of other covariates. The data analysis was conducted using SAS 9.1. 
RESULTS: The 2006 NHDS included records of 39,751 women hospitalized for child 
birth; of which 15.25% (N = 6,063) had diagnosis of one or more PEC’s in contrast 
to 4.9% in early 2000’s. PEC’s group had higher proportion of older women 
(≥35years) (20.32% vs. 16.43%, p < 0.0001) and African-Americans (23.50% vs. 
15.79%, p < 0.0001) compared to the non-PEC’s group. Presence of PEC’s was found 
to be associated with prolonged LOS (hazard ratio = 0.840, p < 0.0001). Among 
hospital characteristics, women delivering in large hospitals (≥500beds) (hazard ratio 
= 0.880, p < 0.0001) and northeastern and southern regions (hazard ratio = 0.813, p 
< 0.0001) had extended LOS. In addition, African-American race (hazard ratio = 
0.863, p < 0.0001) and cesarean delivery (hazard ratio = 0.383, p < 0.0001) were also 
associated with longer LOS. CONCLUSIONS: Women with PEC’s impose signiﬁcant 
health care burden in terms of length of stay during child birth. Access to appropriate 
pre-conception and prenatal care should be ensured to childbearing women, especially 
due to the rising prevalence of PEC’s. Racial and geographical disparities need to be 
examined by policy-makers while framing prophylactic strategies. Future research 
should assess the health care resource utilization due to maternal morbidity from 
pre-conception to postpartum period.
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OBJECTIVES: The goal of this study is to describe the timing of the Hypoactive Sexual 
Desire Disorder (HSDD) diagnosis with that of depression/anxiety in a subgroup of 
women suffering from both disorders and determine which diagnosis came ﬁrst—
depression/anxiety or HSDD. In addition it describes the use of both antidepressants 
and anxiolytics in this subgroup. METHODS: Marketscan® Research Databases were 
used to identify women aged 18–64 with an ICD-9-CM coded diagnosis of HSDD 
(302.71) from January 1, 1998-December 31, 2007 who also had an ICD-9-CM coded 
diagnosis of depression or anxiety (293.84, 296.2x, 296.3x, 300.0x, 300.4, 309.1, 
311, v79.0). The ﬁrst physician visit with an HSDD diagnosis was the index date. 
Antidepressant and anxiolytic use was examined in the 24-month study period (12-
months before and following index). RESULTS: A total of 957 (24.1%) of 3,975 
women identiﬁed with HSDD also had a diagnosis of anxiety or depression in the 
study period. In this group, 34.7% (n = 332) had a depression/anxiety-coded claim 
appear after their HSDD-coded claim (after cohort), conversely, 65.3% (n = 625) had 
a depression/anxiety-coded claim appear on or before their HSDD-coded claim (before 
cohort). The majority of women in both the after and before cohorts were prescribed 
an antidepressant or anxiolytic in the study period, 78.3% (n = 260) and 86.1% (n 
= 538) respectively. Sixty percent (n = 156) and sixty-ﬁve percent (n = 351) of these 
women went on to discontinue use of the same. CONCLUSIONS: Over 24% of 
women with HSDD also suffer with depression/anxiety. More than one-third of these 
women developed their depression/anxiety diagnosis after being diagnosed with 
HSDD. A larger proportion of women had a diagnosis of depression and/or anxiety 
on or before that of HSDD. This may be evidence that both depression/anxiety and 
HSDD often present in tandem and that doctors feel competent to make such diag-
noses concurrently. Additionally, intervention with antidepressants or anxiolytics 
appear inadequate to treat this population.
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OBJECTIVES: We sought to evaluate the prevalence of polypharmacy, and to deter-
mine patient characteristics that are predictive of exposure to polypharmacy in the 
elderly population of Emilia-Romagna, Italy. METHODS: We conducted a retrospec-
tive cohort study of the 2007 Emilia-Romagna outpatient pharmacy database linked 
with patient information available from a demographic ﬁle of approximately 1 million 
Emilia-Romagna residents aged ≥65 years. The cohort was comprised of 887,165 
elderly patients who had at least one prescription ﬁlled during the study year. Using 
the World Health Organization’s Deﬁned Daily Dose (DDD) to determine the duration 
of treatment for a given drug, we deﬁned a polypharmacy episode as overlapping 
treatment with 5 or more medications occurring for at least one day. The prevalence 
of polypharmacy was measured together with patient characteristics found to be 
predictive of polypharmacy exposure. RESULTS: A total of 349,689 elderly in the 
population (39.4%) were exposed to at least one episode of polypharmacy. The 
prevalence of polypharmacy substantially increased with age, (32.7% for those ages 
65–74, over 45% for those ages 75+). Over 35% of those exposed to polypharmacy 
were exposed for 101 or more days of the year. The top three classes of medications 
involved in polypharmacy were antithrombotics, peptic ulcer disease and gastro-
esophageal reﬂux disease agents, and angiotensin-converting enzyme inhibitors. Com-
pared to unexposed subjects, elderly exposed to polypharmacy were older, were more 
likely to be male, and had a greater number of chronic conditions. CONCLUSIONS: 
This study provides evidence that the prevalence of polypharmacy in the elderly in 
Emilia-Romagna is substantial. Educational programs targeting primary care physi-
cians should be developed to make them aware of the magnitude of polypharmacy 
phenomenon, as well of patient characteristics associated with polypharmacy to ensur-
ing safe, effective, and appropriate use of medication in the elderly population.
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OBJECTIVES: Non-medical use of prescription drugs (NMPUD) is a serious problem 
in the US. This problem is even more concerning among pregnant women since non-
medical use of prescription drugs has the potential to harm both mother and fetus. 
However, our knowledge about the prevalence of NMPUD among pregnant women 
and its predictors is limited. This study attempted to ﬁll these gaps. Objectives of this 
study were: 1) To estimate the prevalence of NMUPD among pregnant women, and 
2) To determine various predictors of NMUPD among pregnant women. METHODS: 
This study used data from 2007 National Survey on Drug Use and Health (NSDUH). 
Sample consisted of non-institutionalized, pregnant women who were 12 years or 
older. Multiple logistic regression analyses which adjusted for the complex survey 
design were conducted to estimate the relationship between NMUPD among pregnant 
women and demographic characteristics. RESULTS: The sample consisted of 956 
respondents out of which 92 (9.62%) had engaged in NMUPD in the past year. 
Among different categories of prescription drugs, prevalence of non-medical use was 
highest for pain relievers (5.27%), followed by tranquilizers (1.65%), stimulants 
(1.93%), and sedatives (0.51%). Results from the logistic regression showed signiﬁ-
cant relationships between past year NMUPD and poor health status (O.R. = 5.28, 
95% CI: 1.37–20.28), past year use of tobacco (O.R. = 2.28, 95% CI: 1.003–5.226), 
and African American race (O.R. = 0.19, 95% CI: 0.06–0.52) or other nonwhite races 
(O.R. = 0.08, 95% CI: 0.02–0.29) at α = 0.05. CONCLUSIONS: Pain relievers are 
used most frequently non-medically by pregnant women when compared to the other 
prescription drugs. Pregnant women, who are white, have poorer health and those 
who smoke are more likely to engage in NMUPD than the others. This study highlights 
the group of pregnant women that are more vulnerable to NMUPD. Physician need 
to be careful while prescribing medication to these high risk groups.
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Rankin J1, Martin CR2
1University of the West of Scotland, Paisley, UK, 2University of the West of Scotland, 
Ayr, UK
OBJECTIVES: It is assumed within the context of clinical trials that the measurement 
characteristics of self-report outcomes are equivalent. However, little work has been 
conducted to determine if this assumption is supported. The goal of the current study 
was to determine trial allocation may signiﬁcantly impact on the psychometric proper-
ties of a commonly used self-report postnatal depression screening questionnaire. 
METHODS: Utilising data from a prospective randomised controlled trial (RCT) 
investigating the impact of antenatal exercise on psychological well-being, postnatal 
depression was assessed using the Edinburgh Postnatal Depression Scale (EPDS) at the 
12–16 weeks following birth. Structural equation modeling approaches were used to 
investigate the assumption of measurement invariance of the EPDS using a two-
